ArticleAntibiotics (Basel, Switzerland)2021
Effect of
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Trial
- Targeting sepsis through inflammation and oxidative metabolism.World journal of critical care medicine · 2025Review
- N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care.Drugs in context · 2025Review
- Recent advances in understanding oxidative stress in sepsis: pathogenic roles and antioxidant therapeutic prospects - a narrative review.Frontiers in pharmacology · 2025Review
- The effects of antioxidant supplementation on short-term mortality in sepsis patients.Heliyon · 2024Article
- Editorial: New therapeutic strategies against carbapenem-resistant gram-negative bacteria.Frontiers in microbiology · 2024Article
- Editorial: Enterobacteriaceae antimicrobial agents and resistance: relationship with the therapeutic approach, volume II.Frontiers in cellular and infection microbiology · 2024Article
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- Review
- Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producingJAC-antimicrobial resistance · 2022Article
- N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions.Journal of infection and public health · 2022Review
- High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Carbapenem-resistantFrontiers in microbiology · 2022Review
- The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit.Medicina (Kaunas, Lithuania) · 2021Article
- Editorial: Enterobacteriaceae Antimicrobial Agents and Resistance: Relationship With the Therapeutic Approach.Frontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.